99mTc-MIBI in the evaluation of breast cancer biology
- 23 April 2004
- journal article
- review article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 31 (S1) , S88-S96
Abstract
A major area of interest in nuclear medicine is the scintigraphic in vivo evaluation of complex cellular processes involved in tumour growth, progression and response to treatment with the aim of defining the biological properties that may orient clinicians towards different adjustments of therapy in individual patients. In the last decade, 99mTc-labelled lipophilic cations emerged as suitable tools to trace specific cellular processes and functions in a variety of malignant tumours, including breast cancer. Among these agents, 99mTc-methoxyisobutylisonitrile (MIBI) is the most widely evaluated tracer and may serve as a paradigm for this class of compounds. Many clinical studies have been performed to correlate 99mTc-MIBI uptake or clearance with histological, molecular and biochemical markers of various cellular processes, including apoptosis, proliferation, P-glycoprotein expression and neoangiogenesis. The final picture emerging from these studies is that the early tracer uptake reflects the mitochondrial status, which is affected by both apoptosis and proliferation, whereas the tracer clearance reflects the activity of drug transporters such as P-glycoprotein. On the basis of the imaging parameter chosen for the analysis of 99mTc-MIBI scan in breast cancer patients, the biological information provided may be related to different cellular processes that ultimately govern tumour response to treatment.Keywords
This publication has 77 references indexed in Scilit:
- Nuclear medicine applications in molecular imagingJournal of Magnetic Resonance Imaging, 2002
- Identification of Angiogenesis in Primary Breast Carcinoma According to the Image AnalysisBreast Cancer Research and Treatment, 2002
- Prediction of chemotherapeutic response by technetium 99m-MIBI scintigraphy in breast carcinoma patientsCancer, 2001
- Breast cancer cellular proliferation indexes and 99mTc-sesta Mibi capture: what correlation?2001
- Mitochondria as the central control point of apoptosisTrends in Cell Biology, 2000
- Comparative Study of Tc-99m MIBI and Tl-201 SPECT in Predicting Chemotherapeutic Response in Non–Small-Cell Lung CancerClinical Nuclear Medicine, 2000
- Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapyBreast Cancer Research and Treatment, 1998
- E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction.Genes & Development, 1997
- Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria BlockedScience, 1997
- Apoptosis in Toremifene-Induced Growth Inhibition of Human Breast Cancer Cells In Vivo and In VitroJNCI: Journal of the National Cancer Institute, 1993